Sanofi (SNYNF) Deferred Taxes (2013 - 2021)

Sanofi has disclosed Deferred Taxes across 4 years of filings, most recently posting -$19.6 million for Q4 2021.

• Deferred Taxes for Q4 2021 came in at -$19.6 million, up 1.75% year-over-year; the trailing twelve-month figure through Dec 2021 was $728.8 million (changed N/A YoY), and the FY2025 annual result was -$2.8 billion, down 231.28% from the prior year.
• Deferred Taxes came in at -$19.6 million for Q4 2021 at Sanofi, up from -$19.9 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of -$19.6 million in Q4 2021 to a low of -$23.0 million in Q4 2019.
• The 3-year median for Deferred Taxes is -$19.9 million (2020), against an average of -$20.8 million.
• Across the five-year window, Deferred Taxes rose 13.52% in 2020 and gained 1.75% in 2021, its largest moves.
• Sanofi's Deferred Taxes stood at -$23.0 million in 2019, then gained by 13.52% to -$19.9 million in 2020, then grew by 1.75% to -$19.6 million in 2021.
• The last three Deferred Taxes figures came in at -$19.6 million (Q4 2021), -$19.9 million (Q4 2020), and -$23.0 million (Q4 2019), per Business Quant data.